In January 2015 the assets of Aeris Therapeutics Inc. were put up fro auction and was acquired by Pulmonx Corporation. Aeris now functions as a subsiduary of that firm. Aeris Therapeutics, Inc. had been developing novel treatments for patients with advanced lung disease. The Companyâs lead product is a Bronchoscopic Lung Volume Reduction (BLVR) System for the treatment of emphysema. Reduction of lung volume by surgical resection of tissue is an accepted therapy for patients with advanced emphysema. The BLVR System is designed to reduce lung volume non-surgically, by promoting collapse and contraction of the diseased lung tissue. Reduction of lung volume generates more space within the chest cavity, allowing healthier lung tissue to expand and improving lung function and breathing mechanics.
